Amaravathi, M (2016) Thyroid Dysfunction caused by Tyrosine Kinase Inhibitors in Philadelphia Chromosome Positive Chronic Myeloid Leukemia. Masters thesis, Madras Medical College, Chennai.
|
Text
200100116amaravathi .pdf Download (8MB) | Preview |
Abstract
BACKGROUND: Thyroid dysfunction is a known adverse effect of tyrosine kinase inhibitors. Imatinib shown to induce overt hypothyroidism in hypothyroid patients. Very few retrospective studies are available for CML patients treated with Imatinib, which have demonstrated conflicting effects on thyroid function. AIMS AND OBJECTIVES: To investigate the effect of tyrosine kinase inhibitors on thyroid function. Study design: We have prospectively studied Thyroid function before the start of Imatinib therapy and during the course of minimum 6 months duration of therapy in 100 Philadelphia chromosome positive CML patients. RESULTS: Out of 100 patients before imatinib therapy, 9% showed subclinical hypothyroidism and 91% showed euthyroid status. After 6 months of treatment, 5% were hypothyroid out of 91% patients and 9% of Patients with subclinical hypothyroidism had worsening of thyroid profile. CONCLUSION: Although the incidence of hypothyroidism in our study population was insignificant the presence of statistically significant TSH increase makes it mandatory to screen thyroid profile in CML patients before the start of tyrosine kinase inhibitors.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg.No.201311018 |
| Uncontrolled Keywords: | chronic myeloid leukemia (CML) ; Imatinib ; TSH ; FT3 ; FT4. |
| Subjects: | MEDICAL > General Medicine |
| Depositing User: | Subramani R |
| Date Deposited: | 06 Feb 2019 09:49 |
| Last Modified: | 06 Feb 2019 09:49 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/10522 |
Actions (login required)
 |
View Item |
